Osteoclasts direct bystander killing of bone cancer

Cancer Research

Volumn 66, Issue 22, 2006, Pages 10929-10935

  Ramnaraine, Margaret L ^a   Mathews, Wendy E ^a   Donohue, James M ^a   Lynch, Christine M ^a   Goblirsch, Michael J ^a   Clohisy, Denis R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CYTOSINE DEAMINASE; FLUCYTOSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE CANCER; BYSTANDER EFFECT; CANCER REGRESSION; CELL COUNT; CELL CULTURE; CELL KILLING; CELL LINEAGE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; ENZYME REGULATION; GENE DELIVERY SYSTEM; GENE EXPRESSION; MOUSE; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL;

ACID PHOSPHATASE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BONE NEOPLASMS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOSINE DEAMINASE; FLUCYTOSINE; GENE THERAPY; ISOENZYMES; MICE; MICE, INBRED C3H; MICE, TRANSGENIC; OSTEOCLASTS; PROMOTER REGIONS (GENETICS); SARCOMA;

EID: 33845303559     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1295     Document Type: Article

References (36)

1. Barresi V, Belluardo N, Sipione S, Mudo G, Cattaneo E, Condorelli DF. Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy. Cancer Gene Ther 2003;10:396-402.
2. Chung-Faye GA, Chen MJ, Green NK, et al. In vivo gene therapy for colon cancer using adenovirus-mediated transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther 2001;8:1547-54.
3. Erbs P, Regulier E, Kintz J, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000;60:3813-22.
4. Greco O, Dachs GU. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol 2001;187:22-36.
5. Kirn D, Niculescu-Duvaz I, Hallden G, Springer CJ. The emerging fields of suicide gene therapy and virotherapy. Trends Mol Med 2002;8:S68-73.
6. Ramnaraine M, Pan W, Goblirsch M, et al. Direct and bystander killing of sarcomas by novel cytosine deaminase fusion gene. Cancer Res 2003;63:6847-54.
7. Wei J, Blum S, Unger M, et al. Embryonic endothelial progenitor cells armed with a suicide gene target hypoxic lung metastases after intravenous delivery. Cancer Cell 2004;5:477-88.
8. Ramnaraine M, Pan W, Clohisy DR. Osteoclasts direct bystander killing of cancer cells in vitro. Bone 2006;38:4-12.
9. Rosen LS, Gordon DH, Dugan W, Jr., et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100:36-43.
10. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76.
11. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082-90.
12. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66:605-12.
13. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64.
14. Yang TT, Sabokbar A, Gibbons CL, Athanasou NA. Human mesenchymal tumour-associated macrophages differentiate into osteoclastic bone-resorbing cells. J Bone Joint Surg Br 2002;84:452-6.
15. Pan W, Mathews W, Donohue JM, et al. Analysis of distinct tartrate-resistant acid phosphatase promoter regions in transgenic mice. J Biol Chem 2004;280:4888-93.
16. Wacnik PW, Baker CM, Herron MJ, et al. Tumor-induced mechanical hyperalgesia involves CGRP receptors and altered innervation and vascularization of DsRed2 fluorescent hindpaw tumors. Pain 2005;115:95-106.
17. Senter PD, Su PCD, Katsuragi T, et al. Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates. Bioconjug Chem 1991;2:447-51.
18. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
19. Clohisy DR, Ogilvie CM, Carpenter RJ, Ramnaraine ML. Localized, tumor-associated osteolysis involves the recruitment and activation of osteoclasts. J Orthop Res 1996;14:2-6.
20. Goblirsch M, Mathews W, Lynch C, Mantyh PW, Clohisy DR. Radiation decreases bone cancer pain through direct effects on tumor cells. Radiat Res 2005;164:400-8.
21. Goblirsch M, Mathews W, Lynch C, et al. Radiation treatment decreases bone cancer pain, osteolysis and tumor size. Radiat Res 2004;161:228-34.
22. Reddy SV, Roodman GD. Control of osteoclast differentiation. Crit Rev Eukaryot Gene Expr 1998;8:1-17.
23. Menaa C, Devlin RD, Reddy SV, Gazitt Y, Choi SJ, Roodman GD. Annexin II increases osteoclast formation by stimulating the proliferation of osteoclast precursors in human marrow cultures. J Clin Invest 1999;103:1605-13.
24. Goblirsch M, Zwolak P, Ramnaraine ML, et al. Novel cytosine deaminase fusion gene enhances radiation's effect on breast cancer in bone by reducing tumor burden, osteolysis, and skeletal fracture. Clin Cancer Res 2006;12:3168-76.
25. Chung-Faye GA, Chen MJ, Green NK, et al. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther 2001;8:1547-54.
26. Boucher PD, Im MM, Freytag SO, Shewach DS. A novel mechanism of synergistic cytotoxicity with 5-fluorocytosine and ganciclovir in double suicide gene therapy. Cancer Res 2006;66:3230-7.
27. Lee KC, Hamstra DA, Bullarayasamudram S, et al. Fusion of the HSV-1 tegument protein vp22 to cytosine deaminase confers enhanced bystander effect and increased therapeutic benefit. Gene Ther 2006;13:127-37.
28. Wygoda MR, Wilson MR, Davis MA, Trosko JE, Rehemtulla A, Lawrence TS. Protection of herpes simplex virus thymidine kinase-transduced cells from ganciclovir-mediated cytotoxicity by bystander cells: the Good Samaritan effect. Cancer Res 1997;57:1699-703.
29. Burgess TL, Qian Y, Kaufman S, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999;145:527-38.
30. Freytag SO, Stricker H, Pegg J, et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 2003;63:7497-506.
31. Pandha HS, Martin LA, Rigg A, et al. Genetic prodrug activation therapy for breast cancer: a phase I clinical trial of erbB-2-directed suicide gene expression. J Clin Oncol 1999;17:2180-9.
32. Koong AC, Denko NC, Hudson KM, et al. Candidate genes for the hypoxic tumor phenotype. Cancer Res 2000;60:883-7.
33. Shibata T, Giaccia AJ, Brown JM. Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Ther 2000;7:493-8.
34. Marples B, Scott SD, Hendry JH, Embleton MJ, Lashford LS, Margison GP. Development of synthetic promoters for radiation-mediated gene therapy. Gene Ther 2000;7:511-7.
35. Kufe D, Weichselbaum R. Radiation therapy: activation for gene transcription and the development of genetic radiotherapy-therapeutic strategies in oncology. Cancer Biol Ther 2003;2:326-9.
36. Staba MJ, Mauceri HJ, Kufe DW, Hallahan DE, Weichselbaum RR. Adenoviral TNF-α gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther 1998;5:293-300.